6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
are	VBP	are	are	are	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Dyax	NNP	dyax	dyax	dyax	N	O
Corp	NNP	corp	corp	corp	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
452	CD	452	452	452	N	O
-	:	-	-	-	N	O
5248	CD	5248	5248	5248	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
in	IN	in	in	in	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
HAE	NNP	hae	hae	hae	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
or	CC	or	or	or	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
66%	CD	66%	66%	66%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
86%	CD	86%	86%	86%	N	O
were	VBD	were	were	were	N	O
Caucasian	JJ	caucasian	caucasian	caucasian	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
were	VBD	were	were	were	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
ages	NNS	ages	age	age	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
and	CC	and	and	and	N	O
78	CD	78	78	78	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
HAE	NNP	hae	hae	hae	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nasopharyngitis	FW	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
HAE	NNP	hae	hae	hae	N	O
.	.	.	.	.	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
characterized	VBN	characterized	characterized	character	N	O
by	IN	by	by	by	N	O
local	JJ	local	local	local	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
irritation	NN	irritation	irritation	irrit	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
bruising	NN	bruising	bruising	bruis	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
below	IN	below	below	below	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
upon	IN	upon	upon	upon	N	O
2	CD	2	2	2	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
EDEMA3	NNP	edema3	edema3	edema3	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
EDEMA4	NNP	edema4	edema4	edema4	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
143	CD	143	143	143	N	O
unique	JJ	unique	unique	uniqu	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
HAE	NNP	hae	hae	hae	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
permitted	VBN	permitted	permitted	permit	N	O
to	TO	to	to	to	N	O
participate	VB	participate	participate	particip	N	O
sequentially	RB	sequentially	sequentially	sequenti	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
placebo	FW	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
;	:	;	;	;	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
collected	VBD	collected	collected	collect	N	O
during	IN	during	during	dure	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
was	VBD	was	wa	wa	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
collected	VBD	collected	collected	collect	N	O
during	IN	during	during	dure	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
that	WDT	that	that	that	N	O
also	RB	also	also	also	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
EDEMA3	NNP	edema3	edema3	edema3	N	O
and	CC	and	and	and	N	O
EDEMA4	NNP	edema4	edema4	edema4	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
Higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Controlled	NNP	controlled	controlled	control	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
HAE	NNP	hae	hae	hae	N	O
Treated	NNP	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O

a	DT	a	a	a	N	O
Patients	NNPS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
event	NN	event	event	event	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
preferred	JJ	preferred	preferred	prefer	N	O
term	NN	term	term	term	N	O
are	VBP	are	are	are	N	O
counted	VBN	counted	counted	count	N	O
only	RB	only	only	onli	N	O
once	RB	once	once	onc	N	O
for	IN	for	for	for	N	O
that	DT	that	that	that	N	O
preferred	JJ	preferred	preferred	prefer	N	O
term	NN	term	term	term	N	O
.	.	.	.	.	N	O

KALIBITORN	NNP	kalibitorn	kalibitorn	kalibitorn	N	O

100	CD	100	100	100	N	O
PlaceboN	NNP	placebon	placebon	placebon	N	O
81	CD	81	81	81	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
a	DT	a	a	a	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
a	DT	a	a	a	N	O

Headache	NN	headache	headache	headach	Y	B-AdverseReaction

8	CD	8	8	8	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
EDEMA3	NNP	edema3	edema3	edema3	N	O
and	CC	and	and	and	N	O
EDEMA4	NNP	edema4	edema4	edema4	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
second	JJ	second	second	second	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
within	IN	within	within	within	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
the	DT	the	the	the	N	O
additional	JJ	additional	additional	addit	N	O
30	CD	30	30	30	N	O
mg	NN	mg	mg	mg	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
were	VBD	were	were	were	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
those	DT	those	those	those	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
HAE	NNP	hae	hae	hae	N	O
program	NN	program	program	program	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
.	.	.	.	.	N	O

Rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
seroconversion	NN	seroconversion	seroconversion	seroconvers	N	O
increased	VBN	increased	increased	increas	N	O
with	IN	with	with	with	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
over	IN	over	over	over	N	O
time	NN	time	time	time	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
20.2%	CD	20.2%	20.2%	20.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
seroconverted	VBN	seroconverted	seroconverted	seroconvert	N	O
to	TO	to	to	to	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
ecallantide	NN	ecallantide	ecallantide	ecallantid	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
ecallantide	VB	ecallantide	ecallantide	ecallantid	N	O
were	VBD	were	were	were	N	O
determined	VBN	determined	determined	determin	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
present	JJ	present	present	present	N	O
in	IN	in	in	in	N	O
8.8%	CD	8.8%	8.8%	8.8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
.	.	.	.	.	N	O

Anti	NNP	anti	anti	anti	N	O
-	:	-	-	-	N	O
ecallantide	NN	ecallantide	ecallantide	ecallantid	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
for	IN	for	for	for	N	O
tested	JJ	tested	tested	test	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
P.	NNP	p.	p.	p.	N	O
pastoris	FW	pastoris	pastoris	pastori	N	O
IgE	NNP	ige	ige	ige	Y	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
detected	VBN	detected	detected	detect	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
20.2%	CD	20.2%	20.2%	20.2%	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
seroconvert	VBP	seroconvert	seroconvert	seroconvert	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
test	NN	test	test	test	N	O
results	NNS	results	result	result	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
ecallantide	JJ	ecallantide	ecallantide	ecallantid	N	O
program	NN	program	program	program	N	O
were	VBD	were	were	were	N	O
determined	VBN	determined	determined	determin	N	O
using	VBG	using	using	use	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
two	CD	two	two	two	N	O
assay	JJ	assay	assay	assay	N	O
formats	NNS	formats	format	format	N	O
:	:	:	:	:	N	O
ELISA	NNP	elisa	elisa	elisa	Y	O
and	CC	and	and	and	N	O
bridging	VBG	bridging	bridging	bridg	N	O
electrochemiluminescence	NN	electrochemiluminescence	electrochemiluminescence	electrochemiluminesc	N	O
(	(	(	(	(	N	O
ECL	NNP	ecl	ecl	ecl	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
proteins	NNS	proteins	protein	protein	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
formation	NN	formation	formation	format	N	O
is	VBZ	is	is	is	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibody	NN	antibody	antibody	antibodi	N	O
)	)	)	)	)	N	O
positivity	NN	positivity	positivity	posit	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
influenced	VBN	influenced	influenced	influenc	N	O
by	IN	by	by	by	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
KALBITOR	VB	kalbitor	kalbitor	kalbitor	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

Similar	JJ	similar	similar	similar	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
for	IN	for	for	for	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	JJ	estimate	estimate	estim	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
with	IN	with	with	with	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n	VBZ	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
\n\n	RBR	\n\n	\n\n	\n\n	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
healthcare	JJ	healthcare	healthcare	healthcar	N	O
professional	JJ	professional	professional	profession	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
.	.	.	.	.	N	O

Healthcare	NNP	healthcare	healthcare	healthcar	N	O
professionals	NNS	professionals	professional	profession	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
aware	JJ	aware	aware	awar	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
similarity	NN	similarity	similarity	similar	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
between	IN	between	between	between	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
clinical	JJ	clinical	clinical	clinic	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
.	.	.	.	.	N	O

[\n\n	JJ	[\n\n	[\n\n	[\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]\n\n	NN	]\n\n	]\n\n	]\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
EXCERPT	NNP	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
ANAPHYLAXIS	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
,	,	,	,	,	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
healthcare	JJ	healthcare	healthcare	healthcar	N	O
professional	JJ	professional	professional	profession	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
support	NN	support	support	support	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
\n\n	JJ	\n\n	\n\n	\n\n	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
.	.	.	.	.	N	O

Healthcare	NNP	healthcare	healthcare	healthcar	N	O
professionals	NNS	professionals	professional	profession	N	O
should	MD	should	should	should	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
be	VB	be	be	be	N	O
aware	JJ	aware	aware	awar	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
similarity	NN	similarity	similarity	similar	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
between	IN	between	between	between	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
\n\n	VBP	\n\n	\n\n	\n\n	N	O
and	CC	and	and	and	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
clinical	JJ	clinical	clinical	clinic	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
[\n\n	NNP	[\n\n	[\n\n	[\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
\n	CC	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
Including	NNP	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
:	:	:	:	:	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Administer	NNP	administer	administer	administ	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
setting	NN	setting	setting	set	N	O
equipped	VBN	equipped	equipped	equip	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
hereditary	JJ	hereditary	hereditary	hereditari	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
.	.	.	.	.	N	O

Given	VBN	given	given	given	N	O
the	DT	the	the	the	N	O
similarity	NN	similarity	similarity	similar	N	O
in	IN	in	in	in	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	O
HAE	NNP	hae	hae	hae	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
for	IN	for	for	for	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
Including	VBG	including	including	includ	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O

Potentially	RB	potentially	potentially	potenti	N	B-Factor
serious	JJ	serious	serious	seriou	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
255	CD	255	255	255	N	O
HAE	NNP	hae	hae	hae	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
or	CC	or	or	or	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
10	CD	10	10	10	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
the	DT	the	the	the	N	O
subgroup	NN	subgroup	subgroup	subgroup	N	O
of	IN	of	of	of	N	O
187	CD	187	187	187	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
included	VBN	included	included	includ	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
flushing	NN	flushing	flushing	flush	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngeal	NN	pharyngeal	pharyngeal	pharyng	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
rhinorrhea	NN	rhinorrhea	rhinorrhea	rhinorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
sneezing	VBG	sneezing	sneezing	sneez	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
,	,	,	,	,	N	O
throat	NN	throat	throat	throat	N	B-AdverseReaction
irritation	NN	irritation	irritation	irrit	N	I-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
wheezing	NN	wheezing	wheezing	wheez	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
hour	NN	hour	hour	hour	N	O
after	IN	after	after	after	N	O
dosing	VBG	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
indicative	VBP	indicative	indicative	indic	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
included	VBD	included	included	includ	N	O
the	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
:	:	:	:	:	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
time	NN	time	time	time	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
,	,	,	,	,	N	O
taking	VBG	taking	taking	take	N	O
into	IN	into	into	into	N	O
account	NN	account	account	account	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Given	VBN	given	given	given	N	O
the	DT	the	the	the	N	O
similarity	NN	similarity	similarity	similar	N	O
in	IN	in	in	in	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	O
HAE	NNP	hae	hae	hae	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
clinical	JJ	clinical	clinical	clinic	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
to	TO	to	to	to	N	O
KALBITOR	NNP	kalbitor	kalbitor	kalbitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

